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Abstract CYP2D6 is a critical pharmacogenetic target, and
polymorphisms in the gene region are commonly used to infer
enzyme activity score and predict resulting metabolizer phe-
notype: poor, intermediate, extensive/normal, or ultrarapid
which can be useful in determining cause and/or manner of
death in some autopsies. Current genotyping approaches are
incapable of identifying novel and/or rare variants, so
CYP2D6 star allele definitions are limited to polymorphisms
known a priori. While useful for most predictions, recent stud-
ies using massively parallel sequencing data have identified
additional polymorphisms in CYP2D6 that are predicted to
alter enzyme function but are not considered in current star
allele nomenclature. The 1000 Genomes Project data were
used to produce full-gene haplotypes, describe their distribu-
tion in super-populations, and predict enzyme activity scores.
Full-gene haplotypes generated lower activity scores than cur-
rent approaches due to inclusion of additional damaging poly-
morphisms in the star allele. These findings are critical for
clinical implementation of metabolizer phenotype prediction
because a fraction of the population may be incorrectly con-
sidered normal metabolizers but actually may be poor or in-
termediate metabolizers.
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Introduction
The cytochrome p450 family 2 subfamily D polypeptide 6
(CYP2D6) enzyme is part of a large family of CYPs respon-
sible for a substantial portion of hepatic phase I metabolism of
foreign compounds and endogenous toxins [1, 2]. The en-
zyme has been implicated in drug metabolism variation of
clinical and medico-legal relevance [3, 4]. Current methods
of pharmacogene analyses employ targeted approaches, such
as genome wide association studies of candidate single nucle-
otide polymorphisms (SNPs) and SNP-targeted massively
parallel sequencing (MPS) of known a priori SNPs and/or
insertion/deletion polymorphisms (INDELs) [5]. The
CYP2D6 allele nomenclature, in the Human Cytochrome
P450 Allele Nomenclature Database (HCYPAND) [6], iden-
tifies and defines polymorphisms that confer each CYP2D6
star (*) allele (the collection of polymorphisms within the
gene region). CYP2D6 * allele genotypes (g), or diplotypes,
commonly provide inferences of metabolizer phenotype (MP;
poor (gPM), intermediate (gIM), normal/extensive (gNM/
gEM), or ultrarapid (gUM) CYP2D6 activity) [1, 2, 6, 7]. It
has been demonstrated both clinically and medico-legally that
CYP2D6 information can result in increased prescription
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efficacy and inference of idiosyncratic effect during accident
reconstruction [4, 8–11]. In fact, Koren et al. [4] and Koski
et al. [8, 9] have used targeted genotyping ofCYP2D6 to make
inferences regarding the cause and/or manner of death in a
series of medico-legal cases. However, targeted genotyping
approaches inherently are incapable of revealing novel poly-
morphisms that may further refine CYP2D6 * alleles and the
associated metabolic differences observed in clinical cases
and medico-legal investigations. MPS of the full gene region
has the potential to reveal additional polymorphisms and re-
fine predictions of CYP2D6 activity.
Wendt et al. [12] characterized 418 polymorphisms in
CYP2D6 exons, introns, 3′ and 5′ untranslated regions, and
promoter region in the 1000 Genomes Project dataset. Ninety-
seven (23.2%) of the polymorphisms are currently used by
HCYPAND to classify some of the < 150 CYP2D6 * alleles
observed to date. The remaining 321 polymorphisms have a
wide range of allele frequencies in the African (AFR),
Admixed American (AMR), East Asian (EAS), European
(EUR), and South Asian (SAS) super-populations. Most no-
table are those polymorphisms predicted to damage, or most
likely damage, CYP2D6 function. Ignoring these loci when
determining CYP2D6 * alleles may lead to inaccurate predic-
tions of enzyme function and incorrect conclusions for drug
therapy or potential cause and/or manner of death investiga-
tions. The HCYPAND database has established inclusion
criteria for newly observed CYP alleles [13] which put more
emphasis on enzyme-altering polymorphisms for the sake of
providing minimalist nomenclature. However, in medico-
legal autopsy cases where incident reconstruction and cause
and/or manner of death may be inferred from toxicology and
genetic data [4, 8, 9], a more comprehensive and inclusive
nomenclature may be necessary. Herein, all typed loci from
the 1000 Genomes Project data were used to generate and
characterize full-gene CYP2D6 haplotypes. These data indi-
cate that the phenotypic impact of some previously defined
CYP2D6 * alleles may have been mischaracterized due to
damaging polymorphisms occurring elsewhere in the gene
rela t ive to a HCYPAND causal SNP or INDEL.
Mischaracterizations based on targeted genotyping and tradi-
tional * allele nomenclature may have clinical and medico-
legal consequences, as a fraction of 1000 Genomes Project
samples may be inaccurately placed into MP categories.
Materials and methods
Polymorphisms in theCYP2D6 gene region (introns, exons, 5′
and 3′ untranslated regions (UTRs), and promoter) were
downloaded from phase 3 of the 1000 Genomes Project [14,
15] and analyzed individually in 5 super- and 26 sub-
populations (Table S1) according to Wendt et al. 2017 [12].
1000 Genomes Project CYP2D6 haplotypes containing
reportedly phased polymorphisms [16] were aligned to the
hg38 and hg19 reference genomes and the M33388
GenBank accession reference sequence (Table S2) for ease
of community comparison [17] https://www.ncbi.nlm.nih.
gov/nuccore/M33388?report=GenBank, https://www.ncbi.
nlm.nih.gov/nucleotide/45024927 [18]. CYP2D6 full-gene
haplotypes were named relative to the reverse DNA strand
of three reference sequences with the following nomenclature
format: reference sequence (genome name or GenBank
Accession Number)-HCYPAND CYP2D6 * allele
designation-polymorphism rs number, if known, followed by
the base at that position. Note that if an rs number is not
provided for a specific location, the nucleotide position and
base change, relative to the indicated reference, are provided.
For example, haplotype 1 is named M33388-CYP2D6:
5157insCCCACCCCTT, hg19-CYP2D6: rs28439297A;
rs28680494G; rs1080983G; rs1080985C; rs28735595A;
rs28624811C; rs28633410G; rs1808995G; rs1080996C;
rs74644586C; rs76312385T; rs75276289G; rs28695233A;
rs1081000A; rs28371699G; rs28371701C; rs28371702T;
rs1058164G; rs16947C; rs28371730G; rs1135840G;
rs116390392G; rs71184866insACA; rs35028622T;
rs34386013T, and hg38-CYP2D6: none, relative to the
M33388, hg19, and hg38 reference genomes, respectively.
Full-gene CYP2D6 haplotypes and diplotypes for 2504 in-
dividuals in five super- and 26 sub-populations were created
using excel-based workbooks. Private mutations (those poly-
morphisms observed once in the 1000 Genomes dataset), ex-
cept those considered clinically relevant by HCYPAND and
those predicted by Wendt et al. 2017 [12] to damage, or most
likely damage, the resulting protein, were removed from hap-
lotype formation to simplify downstream analyses. 1000
Genomes Project haplotypes were named according to the
same convention described above. Genetic Data Analysis
[19] was used to determine haplotype and diplotype frequen-
cies, observed (Ho) and expected (He) heterozygosities,
pairwise genetic distances, and perform tests for detection of
departures from Hardy-Weinberg Equilibrium (HWE).
TreeView Version 1.6.6 Build 7601 [20, 21] and RStudio®
[22] were used to create phylogenetic trees and multidimen-
sional scaling (MDS) plots, respectively. Network analyses
were performed using Population Analysis with Reticulate
Trees (PopART) [23]. For comparison to HCYPAND
CYP2D6 * alleles, full-gene haplotypes lacking amino acid
changes and damaging intronic sequences are considered de-
rivatives of CYP2D6*1 and full-gene haplotypes conferring
R296C (or C296R for hg19-based haplotypes) and S486T (or
T486S for hg19-based haplotypes), but no other amino acid
changes or damaging intronic polymorphisms were consid-
ered derivatives of CYP2D6*2.
Activity scores were assigned to each allele (i.e., 0, 0.5, 1,
or 2) and individual (i.e., 0, 0.5, 1, 1.5, 2, or 3) in two ways: (1)
Full-gene haplotypes were assigned a most similar
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HCYPAND-recognized allele which was then assigned an
activity score based onGaedigk et al. [24] without considering
the impact of additional polymorphisms not recognized by
HCYPAND [6]. (2) Considering all polymorphisms, a best-
and worst-case activity score were assigned to each full-gene
haplotype. For example, haplotype 33 (M33388-CYP2D6:
310 T; 843G; 1067G; 5157insCCCACCCCTT) received an
activity score of 1 based on the absence of HCYPAND causal
polymorphisms only (resembling a normally active * allele).
The presence of non-HCYPAND intronic polymorphism
rs78854695, 1067G, damages splicing [12], but its specific
impact on CYP2D6 has not been confirmed empirically. So
haplotype 33was assigned best- and worst-case activity scores
of 0.5 and 0, respectively.
Results
Histograms of SIFT [25–30], PolyPhen-v2 [25, 31, 32], and
PROVEAN [33–35] scores from Wendt et al. [12] for
HCYPAND-recognized and non-HCYPAND polymorphisms
(Fig. 1) indicate that 29, 20, and 30 polymorphisms, respec-
tively, from the 1000 Genomes Project dataset for CYP2D6
are predicted to negatively impact protein function. After re-
moval of 138 private mutations, except those considered caus-
al by HCYPAND and those considered damaging or most
likely damaging based on Wendt et al. [12], 446 unique full-
gene haplotype string sequences were observed (Table S2).
Full-gene CYP2D6 haplotypes 11, 3, and 1 are identical to
reference sequences M33388, hg19, and hg38, respectively.
A majority of haplotypes were observed once in the global
population, so the average global frequency of full-gene
CYP2D6 haplotypes was quite low (0.00224 ± 0.0115 with a
range of 0.165 (haplotype 1) to 0.000200 (haplotypes 205
through 446)). Haplotypes 1 through 18, had global frequen-
cies ≥ 1%, with an average frequency of 0.0394 ± 0.0438
(Table 1 and Fig. 2). The average super-population frequen-
cies for haplotypes 1 through 18 were 0.0348 ± 0.0382 in
AFR, 0.0508 ± 0.0832 in AMR, 0.0110 ± 0.0169 in EAS,
0.0539 ± 0.0559 in EUR, and 0.0638 ± 0.102 in SAS.
One haplotype observed in this study was consistent with
HCYPAND CYP2D6 * allele reference list (CYP2D6*1A [6],
M33388-CYP2D6: None, hg19-CYP2D6: rs28439297A;
rs28680494G; rs1080983G; rs1080985C; rs28735595A;
rs28624811C; rs28633410G; rs10808995G; rs1080996C;
rs74644586C; rs76312385T; rs75276289G; rs28695233A;
rs1081000A; rs28371699G; rs28371701C; rs28371702T;
rs1058164G; rs16947C; rs28371730G; rs1135840G;
rs116390392G; rs71184866insACA; rs35028622T;
rs34386013T; rs536156813delCCCACCCCTT, hg38-
CYP2D6: rs536156813delCCCACCCCTT). Though not spe-
cifically reported in the HCYPAND CYP2D6 * allele table,
407 (91.3%) haplotypes could be associated with at least one *
allele based on the presence of defining amino acid changes
and causal polymorphisms; however, 38 (i.e., 8.52%) of them
could not be associated. These 38 haplotypes were observed
125/5008 times (2.50%) in the 1000 Genomes Project and
contain combinations of functionally relevant polymorphisms
[6]. Figure 3 and Figure S1 represent the variant composition
of haplotypes 1 through 18 and all 446 haplotypes, respective-
ly. The average number of polymorphisms per haplotype was
15 ± 10, 20 ± 10, and 14 ± 10 as designated by comparison
with the M33388, hg19, and hg38 reference sequences, re-
spectively. The majority of each haplotype is functionally ir-
relevant polymorphic sites; however, 326, 328, and 326 hap-
lotypes harbor a damaging, or most likely damaging, variant
relative to the M33388, hg19, and hg38 reference genomes,
respectively.
Network analysis was performed to determine the related-
ness of two sets of haplotypes: (1) haplotypes having ≥ 1%
global haplotype frequency (haplotypes 1–18; Fig. 4), and (2)
haplotypes observed more than once in the entire 1000
Genomes Project dataset (haplotypes 1–204; Figure S2). In
Fig. 4 and Figure S2, the haplotypes with relatively low global
frequencies appear to be derived from the major haplotypes
(1, 2, and 3). All major haplotypes except 15 and 17 were
observed in the AFR super-population, though the frequency
is relatively low due to the AFR population having the widest
haplotype spread (Figure S2). Haplotype 9 is exclusive, and
haplotypes 5, 6, 9, 13, and 18 are almost exclusive, to the AFR
super-population. The clustering of rare haplotypes suggests
that these may be specific to one super-population, such as
AFR (minor haplotypes stemming from haplotypes 5, 6, 8,
and 9) or EAS (minor haplotypes stemming from haplotypes
2, 15, and 17).
There were 961 unique diplotypes observed across 2504
individuals. The average global diplotype frequency was
0.00104 ± 0.00336. Ten diplotypes had global frequencies ≥
1%, with an average global frequency of 0.0275 ± 0.0177
(Table 1). The average diplotype frequency in the AFR,
AMR, EAS, EUR, and SAS super-populations was
0.00253 ± 0.00277, 0.00587 ± 0.0133, 0.00658 ± 0.0227,
0.00466 ± 0.00688, and 0.00568 ± 0.0142, respectively
(Fig. 5). The average global Ho and He of CYP2D6 were
0.820 ± 0.0898 and 0.861 ± 0.0923, respectively. Before
Bonferroni correction (p < 0.05), CYP2D6 deviated from
HWE expectations in three super-populations (AFR, AMR,
and EUR) and nine sub-populations (ASW, GWD, LWK,
MSL, YRI, CLM, CDX, CHS, and GBR) (Fig. 6). After
Bonferroni correction (p < 0.00161), CYP2D6 deviated from
HWE expectations in the AFR super-population and the ASW
and LWK sub-populations.
Activity scores were assigned to each individual using the
functional consequence of the most closely related
HCYPAND-recognized * allele to each full-gene haplotype.
Two hundred eighty-two individuals harbor full-gene
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haplotypes that, by HCYPAND nomenclature, should confer
normal activity enzymes (activity score = 1), but full-gene
data reveal additional causal polymorphisms that were pre-
dicted to damage enzyme function (Fig. 7). Twenty-two of
these individuals (21 AFR and 1 AMR) have diplotypes
where two full-gene haplotypes produce conflicting activity
scores relative to the HCYPAND approach. The average indi-
vidual activity scores were 1.40 ± 0.644, 1.36 ± 0.638, and
1.30 ± 0.675 based on HCYPAND guidelines, full-gene best-
(Student’s t test, p < 0.05 relative to the HCYPAND ap-
proach), and full-gene worst-case (Student’s t test, p < 0.001
relative to the HCYPAND approach) haplotype activity score
designation. Haplotype 8 (M33388-CYP2D6: -2060G; -
2053T; -1594C; -1418A; -1408A; -1235G; -740T; 176A;
310T; 744delC; 746G; 843G; 1659A; 1661C; 2123T;
2215G; 2292A; 2850T; 3183A; 4180C; 4719G; 4864C;
5157insCCCACCCCTT) is responsible for the majority of
conflicting MP predictions (111 AFR and 2 AMR individ-
uals). By HCYPAND nomenclature, this haplotype would
be assigned an activity score of 0.5 based on similarity to
CYP2D6*29 [40]; however, full-gene haplotype data reveal
the presence of non-HCYPAND INDEL rs267608275delC
(744delC). Due to lack of empirical observation of the influ-
ence rs267608275delC has on CYP2D6 function, worst- and
best-case activity scores of 0 and 0.5, respectively, were
assigned for full-gene haplotypes, indicating that
rs267608275delC may or may not further decrease CYP2D6
function. This significant decrease in average activity score
suggests that by current CYP2D6 * allele and activity score
designation, ~ 11% of the individuals in this dataset may be
wrongly considered gNM-F, gNM-S, or gIM when they likely
belong in the gNM-S, gIM, and gPM categories, respectively.
MDS plots and unrooted phylogenetic trees (Fig. 8) of
super-populations show distant separation of the AFR and
EAS populations while EUR, AMR, and SAS cluster
relatively close together. Considering sub-populations, those
belonging to the AFR and EAS super-populations cluster to-
gether according to super-population affiliation. Sub-
populations belonging to the AMR, EUR, and SAS super-
populations have considerable overlap with one another.
Discussion
Full-gene CYP2D6 haplotypes may be able to refine MP pre-
dictions, ultimately identifying more gIM and gPM individuals
than the HCYPAND haplotype nomenclature. The analyses
presented here may be limited by the relative low depth of
sequence coverage per sample within the 1000 Genomes
Project database, small sample size for each sub population,
and the precision of variant effect prediction algorithms.
These factors impact detection of rare variants that may con-
tribute to CYP2D6 function. In fact, the splice defects defining
three * alleles (CYP2D6*4, CYP2D6*11, and CYP2D6*41)
were not identified by the software analyses performed in
Wendt et al., and the 843G SNP was incorrectly identified as
damaging [6], emphasizing the importance of using variant
effect predictors with caution and employing multiple predic-
tion algorithms to identify single nucleotide variants of interest
[41]. Additional rare variants will continue to be discovered for
PM, IM, and/or UM individuals and/or isolated populations
such as Finns or Ashkenazi Jews. While potentially contribut-
ing significantly to phenotype, variant effect prediction is not
possible; however, the analysis herein may allow for some
prediction of phenotype using a number of previously unex-
ploited polymorphisms [42–45]. Additional research is needed
(e.g., functional enzyme studies, targeted mutagenesis, and/or
quantitative trait analyses) to empirically characterize the phe-
notype generated from rare polymorphisms, combinations of
rare/deleterious polymorphisms in the same haplotype,
Fig. 1 Distribution of variant effect prediction for Clinical
Pharmacogenetics Implementation Consortium polymorphisms and
those not used for CYP2D6 nomenclature. Distribution of Sort
Intolerant From Tolerant (SIFT) (a) [25–30], Polymorphism
Phenotyping v2 (PolyPhen-v2) (b) [25, 31, 32], and Protein Variant
Effect Analyzer (PROVEAN) (c) [33–35] scores from Wendt et al. [12]
for The Human CYP Allele Nomenclature Database recognized
polymorphisms (black bars) and polymorphisms not considered by the
database (red bars). Arrows indicate the threshold applied to scores from
each algorithm to predict the damaging or benign effect a polymorphism
has on protein function; scores < 0.05, > 0.5, < − 2.5 for SIFT, PolyPhen-
v2, and PROVEAN, respectively, may impact protein function
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1018 Int J Legal Med (2018) 132:1007–1024
Fig. 2 CYP2D6 haplotype frequencies. Observed frequencies of 446
full-gene CYP2D6 haplotypes in five major super-populations (African
(AFR), Admixed American (AMR), East Asian (EAS), European (EUR),
and South Asian (SAS)). The inset graph shows the frequency of those
haplotypes with greater than 30 observations globally
Fig. 3 CYP2D6 haplotype composition. Haplotype composition of 18
full-gene CYP2D6 star alleles, with global frequencies ≥ 1%, aligned to
GenBank accession M33388 (a), hg19 (b), and hg38 (c). Variant effect
predictions performed by Wendt et al. [13] using Sort Intolerant From
Tolerant (SIFT) [25–30], Polymorphism Phenotyping v2 (PolyPhen-v2)
[25, 31, 32], Protein Variant Effect Analyzer (PROVEAN) [33–35], and
Human Splicing Finder [39]
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combinations of deleterious polymorphisms in different genes
that may influence one another, and their distributions in under-
represented populations.
Copy number variation (CNV) of some CYP2D6 * alleles
andCYP2D7 pseudogene conversion do occur in some individ-
uals, namely UMs, and may influence the HWE and LD results
[46]. It is likely that some 1000 Genomes Project individuals
from the AFR super-population carry CNVs based on devia-
tions from HWE expectations [46], but the project does not
explore CNV in detail due to limitations of short-read sequenc-
ing [47, 48]. The data presented herein have been analyzed as
though only two copies of CYP2D6 are present in each individ-
ual, so unless an individual contains the SNP rs1135823G>T
(1617G>T), the UMphenotype was not identified. A number of
unique haplotypes have been identified that may be true haplo-
type observations but may also be attributed to duplication of
two common haplotypes and/or CYP2D7 pseudogene conver-
sions [49, 50]. This phenomenon is particularly true for African
populations which exhibit relatively frequent gene duplications
(up to 30%) [51, 52]. The development of continuous read
single-molecule DNA sequencing strategies, such as nanopore
technology [53], may help reduce ambiguity in sequencing re-
gions with a high degree of structural variation.
Unique haplotypes have been identified from the full-gene
region of CYP2D6, including introns, exons, 5′ and 3′ UTRs,
and the promoter region. While comprehensively assessing
the gene itself, there are a number of distant regulatory ele-
ments that may impact enzyme function. Wang et al. [54]
identified long-range haplotypes that include polymorphisms
within enhancer regions that may refine these haplotype def-
initions. However, inclusion of such regulatory elements in
CYP2D6-based MP predictions may need to be explored fur-
ther due to potential regulation of other enzymes, potentially
confounding MP prediction. Additionally, private mutations
not predicted to damage the resulting protein have been re-
moved (note that those considered for HCYPAND-recognized
* alleles have been included) from this analysis; however, if
incorporated, may produce finer granularity of haplotype def-
inition but likely would not alter activity score unless empir-
ically shown to alter enzyme function.
Full-gene CYP2D6 data have provided additional resolution
to the MP compared to predictions used to date, possibly resolv-
ing some medico-legal autopsy negative cases. Although empir-
ical data are required to confirm their enzyme activity, approxi-
mately 11% of the healthy individuals in this study may be
wrongly identified as NMs according to traditional CYP2D6
genotyping and activity score predictions ofMP. Clinically, these
individuals likely would be classified as IM or PM and be treated
accordingly. Enhanced predictive capabilities of MP may be
made with comprehensive CYP2D6 diplotype information and/
Fig. 4 Network analysis of CYP2D6 haplotypes. Network analysis of
CYP2D6 full-gene haplotypes 1 through 18. The size of each circle is
proportional to the global frequency of each haplotype, segments within
each circle are proportional to the super-population haplotype frequency,
and lines connecting circles are dashed with the number of mutations
separating two haplotypes
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Fig. 5 CYP2D6 diplotype frequencies. Relative CYP2D6 diplotype
frequencies in the global population (a), African (b), Admixed
American (c), East Asian (d), European (e), and South Asian (f) super-
populations. The x- and y-axes indicate the first and second haplotype,
respectively, of an individual diplotype; the size of each solid circle is
proportional to the frequency of that diplotype
Fig. 6 Heterozygosity and Hardy-Weinberg Equilibrium summary.
Observed and expected heterozygosity of CYP2D6 in five major super-
and 26 sub-populations. Super-populations and their associated sub-
populations are color-coded (red for African (AFR), blue for Admixed
American (AMR), green for East Asian (EAS), yellow for European
(EUR), and gray for South Asian (SAS)); the size of each data point
corresponds to the Hardy-Weinberg Equilibrium (HWE) p value for the
locus within that population. The AFR super-population and the Luhya in
Webuye, Kenya (LWK), and American of African Ancestry in Southwest
United States (ASW) sub-populations deviated significantly from HWE
expectations after Bonferroni correction (p < 0.00161)
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Fig. 7 Activity score predictions
using Clinical Pharmacogenetics
Implementation Consortium star
allele nomenclature and full-gene
CYP2D6 haplotypes. Genotype-
inferred (g) CYP2D6 MP (gPM,








CYP2D6 * alleles and full-gene
haplotypes for 2504 1000
Genomes Project self-reported
healthy individuals. Asterisks
indicate significant difference in
average activity score (Student’s t
test; *p < 0.05; ***p < 0.001)
compared with HCYPAND
nomenclature. vertical black bars
indicate the average activity
score ± one standard deviation.
Individuals with combinations of
causal HCYPAND
polymorphisms were not assigned
to a MP using HCYPAND
nomenclature and were assigned
to the Bunknown^ MP category
Fig. 8 Population comparisons using full-gene CYP2D6 haplotypes.
Neighbor-joining trees (a and b) and multidimensional scaling plots (c
and d) for five super- (a and c) and 26 sub-populations (b and d) in the
1000 Genomes Project using pairwise genetic distances based on full-
gene CYP2D6 haplotype assignment
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or incorporation of a longer read sequencing platform into the
CYP2D6 interrogation workflow.
The case described by Koren et al. [4] of an application of
CYP2D6 genotyping to assist in a medico-legal investigation
is a classic example of ultrarapid metabolism of codeine to
morphine. In such cases, the medicaments were delivered as a
pro-drug (inactive) that must be metabolized in order to deliv-
er the intended effect (e.g., codeine or tamoxifen) [1, 2]. Given
the prevalence of UM in various populations and the current
use of these drugs, it is anticipated that similar cases will occur
and molecular autopsies may shed light on the cause and/or
manner of death. At the opposite end of the metabolizer phe-
notype spectrum are PMs and IMs. If considering codeine to
morphine metabolism, CYP2D6 genotyping post-mortem
may not be informative. However, many antidepressants
(e.g., nortriptyline) are active upon administration and depend
on CYP2D6 to deactivate the drug. PMs and IMs, based on
their CYP2D6 variants, may experience adverse reactions to
antidepressants which include, but are not limited to, delayed
propagation of myocardium depolarization leading to cardiac
arrhythmia, myocardial infarction, and death [10]. In the con-
text of the data presented in this study, ~ 11% of individuals
may be incorrectly classified as NMs or IMs as their full-gene
haplotype data indicate one category lower (i.e., NM by
targeted approach is an IM by full-gene approach; IM by
targeted approach is a PM by full-gene approach). As such,
understanding CYP2D6 haplotype information of all
metabolizer phenotypes can be quite relevant to the medico-
legal community.
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